Panitumumab

Drug Profile

Panitumumab

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; Clone-E7.6.3; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Novartis; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Bladder cancer; Breast cancer; Neuroendocrine tumours; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, In infants, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 19 Sep 2017 Takeda completes the phase II SAPPHIRE trial for Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (NCT02337946)
  • 08 Sep 2017 Efficacy and adverse events data from a phase II trial in Colorectal cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top